Sie sind bereits eingeloggt. Klicken Sie auf 2. tolino select Abo, um fortzufahren.
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei bücher.de, um das eBook-Abo tolino select nutzen zu können.
In the face of recent viral outbreaks and a global viral pandemic, the necessity for innovation and continued rapid advancement in viral diagnosis and treatment methods has become even more apparent. Global Virology IV: Viral Disease Diagnosis and Treatment Delivery in the 21st Century explores the latest advances in virology and trends in clinical practice, focused on foundational principles and advancements expected to significantly impact this field. Chapters address SARS-CoV-2, Ebola, Zika, Mpox, and Hepatitis C, among other key viral threats, before presenting a detailed analysis of…mehr
In the face of recent viral outbreaks and a global viral pandemic, the necessity for innovation and continued rapid advancement in viral diagnosis and treatment methods has become even more apparent. Global Virology IV: Viral Disease Diagnosis and Treatment Delivery in the 21st Century explores the latest advances in virology and trends in clinical practice, focused on foundational principles and advancements expected to significantly impact this field. Chapters address SARS-CoV-2, Ebola, Zika, Mpox, and Hepatitis C, among other key viral threats, before presenting a detailed analysis of antiviral agents broadly and concerning specific vulnerable populations such as stem cell and solid organ transplant recipients. It is designed as a helpful resource for medical students, scientists, and professionals, bridging current practice and future applications and inspiring further innovations and improvements in global health.
Charurut Somboonwit, MD Professor Division of Infectious Diseases and International Medicine Department of Internal Medicine University of South Florida Morsani College of Medicine Tampa, FL USA
Paul Shapshak, PhD Professor Division of Infectious Diseases and International Medicine Department of Internal Medicine University of South Florida Morsani College of Medicine Tampa, FL USA
Pandjassarame Kangueane, PhD Director, Biomedical Informatics Private Ltd. Puducherry India
Seetharaman Balaji, PhD Professor, Department of Biotechnology Manipal Institute of Technology Manipal Academy of Higher Education Manipal India
John T. Sinnott, MD, FACP Professor Division of Infectious Diseases and International Medicine Department of Internal Medicine University of South Florida Morsani College of Medicine Tampa, FL USA
Lynnette Menezes, PhD Professor of Medicine Division of Infectious Diseases and International Medicine Associate Vice President International, USF Health Associate Dean International Morsani College of Medicine University of South Florida Tampa, FL USA
Asa Oxner, MD VP, Associate CMO for Ambulatory Services, Tampa General Hospital Medical Director, IDEA Exchange Tampa Assoc. Prof., Dept of Internal Medicine, USF Morsani College of Medicine Medical Director, IDEA Exchange Tampa Department of Internal Medicine University of South Florida Tampa, FL USA
Inhaltsangabe
.- 1. The genome sequence analysis of SARS- CoV-2 variants of concern.- 2. Influenza: Clinical challenges in the 21st century.- 3. Ebola: Virology, clinical considerations, and outbreak response and prevention.- 3. A clinical approach to novel diagnostics and therapeutics: The challenge of Zika.- .5 Oncogenic human papillomavirus.- 6. Hepatitis C virus infection in people who inject drugs.- 7. Hepatitis C: Updates in epidemiology and treatment with direct-acting antivirals.- 8. NeuroAIDS, comorbid mood disorders and neuropsychiatric effects of antiretroviral therapy.- 9. Marijuana and HIV.- 10. Mpox: An emerging global orthopoxvirus outbreak.- 11. Community-acquired respiratory infections in HCT and immunosuppressed patients.- 12. COVID-19 in cancer and hematopoietic stem cell transplant recipients.- 13. Epstein-Barr virus: Acute infection, oncogenesis, prevention and pitfalls.- 14. Human herpesvirus 6A, 6B, 7 and 8 in hematopoietic stem cell transplant: A clinical review.- 15. Cytomegalovirus infections in hematopoietic cell transplant and solid organ transplant recipients.- 16. Herpes simplex virus and varicella zoster virus in hematopoietic stem cell transplant recipients.- 17. The virology of hemophagocytic lymphohistiocytosis.- 18. Antiviral agents: Cidofovir and Brincidofovir.- 19. Antiviral agents: Ganciclovir and valganciclovir.- 20. Antiviral agents: Letermovir.- 21. Antiviral agents: Maribavir.- 22. Antiviral agents in the hematopoietic stem cell transplant population: Acyclovir, valacyclovir, penciclovir and famciclovir.- 23. Antiviral agents in the hematopoietic stem cell transplant population: Foscarnet.- 24. Radioimmunotherapy: An overview.
.- 1. The genome sequence analysis of SARS- CoV-2 variants of concern.- 2. Influenza: Clinical challenges in the 21st century.- 3. Ebola: Virology, clinical considerations, and outbreak response and prevention.- 3. A clinical approach to novel diagnostics and therapeutics: The challenge of Zika.- .5 Oncogenic human papillomavirus.- 6. Hepatitis C virus infection in people who inject drugs.- 7. Hepatitis C: Updates in epidemiology and treatment with direct-acting antivirals.- 8. NeuroAIDS, comorbid mood disorders and neuropsychiatric effects of antiretroviral therapy.- 9. Marijuana and HIV.- 10. Mpox: An emerging global orthopoxvirus outbreak.- 11. Community-acquired respiratory infections in HCT and immunosuppressed patients.- 12. COVID-19 in cancer and hematopoietic stem cell transplant recipients.- 13. Epstein-Barr virus: Acute infection, oncogenesis, prevention and pitfalls.- 14. Human herpesvirus 6A, 6B, 7 and 8 in hematopoietic stem cell transplant: A clinical review.- 15. Cytomegalovirus infections in hematopoietic cell transplant and solid organ transplant recipients.- 16. Herpes simplex virus and varicella zoster virus in hematopoietic stem cell transplant recipients.- 17. The virology of hemophagocytic lymphohistiocytosis.- 18. Antiviral agents: Cidofovir and Brincidofovir.- 19. Antiviral agents: Ganciclovir and valganciclovir.- 20. Antiviral agents: Letermovir.- 21. Antiviral agents: Maribavir.- 22. Antiviral agents in the hematopoietic stem cell transplant population: Acyclovir, valacyclovir, penciclovir and famciclovir.- 23. Antiviral agents in the hematopoietic stem cell transplant population: Foscarnet.- 24. Radioimmunotherapy: An overview.
.- 1. The genome sequence analysis of SARS- CoV-2 variants of concern.- 2. Influenza: Clinical challenges in the 21st century.- 3. Ebola: Virology, clinical considerations, and outbreak response and prevention.- 3. A clinical approach to novel diagnostics and therapeutics: The challenge of Zika.- .5 Oncogenic human papillomavirus.- 6. Hepatitis C virus infection in people who inject drugs.- 7. Hepatitis C: Updates in epidemiology and treatment with direct-acting antivirals.- 8. NeuroAIDS, comorbid mood disorders and neuropsychiatric effects of antiretroviral therapy.- 9. Marijuana and HIV.- 10. Mpox: An emerging global orthopoxvirus outbreak.- 11. Community-acquired respiratory infections in HCT and immunosuppressed patients.- 12. COVID-19 in cancer and hematopoietic stem cell transplant recipients.- 13. Epstein-Barr virus: Acute infection, oncogenesis, prevention and pitfalls.- 14. Human herpesvirus 6A, 6B, 7 and 8 in hematopoietic stem cell transplant: A clinical review.- 15. Cytomegalovirus infections in hematopoietic cell transplant and solid organ transplant recipients.- 16. Herpes simplex virus and varicella zoster virus in hematopoietic stem cell transplant recipients.- 17. The virology of hemophagocytic lymphohistiocytosis.- 18. Antiviral agents: Cidofovir and Brincidofovir.- 19. Antiviral agents: Ganciclovir and valganciclovir.- 20. Antiviral agents: Letermovir.- 21. Antiviral agents: Maribavir.- 22. Antiviral agents in the hematopoietic stem cell transplant population: Acyclovir, valacyclovir, penciclovir and famciclovir.- 23. Antiviral agents in the hematopoietic stem cell transplant population: Foscarnet.- 24. Radioimmunotherapy: An overview.
.- 1. The genome sequence analysis of SARS- CoV-2 variants of concern.- 2. Influenza: Clinical challenges in the 21st century.- 3. Ebola: Virology, clinical considerations, and outbreak response and prevention.- 3. A clinical approach to novel diagnostics and therapeutics: The challenge of Zika.- .5 Oncogenic human papillomavirus.- 6. Hepatitis C virus infection in people who inject drugs.- 7. Hepatitis C: Updates in epidemiology and treatment with direct-acting antivirals.- 8. NeuroAIDS, comorbid mood disorders and neuropsychiatric effects of antiretroviral therapy.- 9. Marijuana and HIV.- 10. Mpox: An emerging global orthopoxvirus outbreak.- 11. Community-acquired respiratory infections in HCT and immunosuppressed patients.- 12. COVID-19 in cancer and hematopoietic stem cell transplant recipients.- 13. Epstein-Barr virus: Acute infection, oncogenesis, prevention and pitfalls.- 14. Human herpesvirus 6A, 6B, 7 and 8 in hematopoietic stem cell transplant: A clinical review.- 15. Cytomegalovirus infections in hematopoietic cell transplant and solid organ transplant recipients.- 16. Herpes simplex virus and varicella zoster virus in hematopoietic stem cell transplant recipients.- 17. The virology of hemophagocytic lymphohistiocytosis.- 18. Antiviral agents: Cidofovir and Brincidofovir.- 19. Antiviral agents: Ganciclovir and valganciclovir.- 20. Antiviral agents: Letermovir.- 21. Antiviral agents: Maribavir.- 22. Antiviral agents in the hematopoietic stem cell transplant population: Acyclovir, valacyclovir, penciclovir and famciclovir.- 23. Antiviral agents in the hematopoietic stem cell transplant population: Foscarnet.- 24. Radioimmunotherapy: An overview.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/neu
